5 Key Takeaways

• 1

  In a 6-month phase 2 study of 30 patients with bilateral geographic atrophy, treated eyes received kamuvudine K8 and fellow eyes served as untreated controls.

• 2

  K8 0.7 mg reduced geographic atrophy growth by 54% in the primary analysis compared with untreated fellow eyes.

• 3

  Piecewise analysis found that K8 0.7 mg reduced growth by 43% during months 0 to 3 and 70% during months 3 to 6, with an overall reduction of 56%.

• 4

  In a prespecified subgroup with nonsubfoveal geographic atrophy, treated eyes had a covariate-adjusted 4-letter visual acuity advantage, although the study was not powered to assess functional outcome

• 5

  No drug-related serious adverse events or dose-limiting toxicities were reported through month 6, but the small study limited conclusions about uncommon adverse events.